Loading…
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $31M | $-229M | $-232M | $-243M | -75.8% | -27.5% | - |
| 2024 | $43M | $-129M | $-131M | $-130M | -38.9% | -6.0% | - |
| 2023 | $46M | $-69M | $-71M | $-2M | -26.6% | 11.1% | - |
| 2022 | $41M | $-97M | $-102M | $-67M | -106.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 41.40 | 46.02 | 43.27 | 31.37 |
| Cost Of Revenue | 8.33 | 4.63 | 3.71 | 2.07 |
| Gross Profit | 33.08 | 41.39 | 39.56 | 29.30 |
| Operating Expense | 112.02 | 116.45 | 185.41 | 272.74 |
| Operating Income | -78.94 | -75.07 | -145.85 | -243.43 |
| EBITDA | -96.62 | -69 | -129.23 | -229.34 |
| EBIT | -99.06 | -69.47 | -130.77 | -231.65 |
| Pretax Income | -102.25 | -70.71 | -130.78 | -231.68 |
| Tax Provision | 0 | 0.08 | 0.09 | 0.28 |
| Net Income | -102.25 | -70.80 | -130.87 | -231.96 |
| Net Income Common Stockholders | -102.25 | -70.80 | -130.87 | -231.96 |
| Total Expenses | 120.34 | 121.08 | 189.13 | 274.81 |
| Interest Expense | 3.19 | 1.25 | 0.01 | 0.03 |
| Interest Income | 2.13 | 6.95 | 15.09 | 11.78 |
| Research And Development | 49.64 | 64.66 | 132.93 | 221.04 |
| Selling General And Administration | 60.32 | 51.79 | 52.49 | 51.70 |
| Normalized EBITDA | -74.36 | -67.65 | -129.23 | -229.34 |
| Normalized Income | -80 | -69.73 | -130.87 | -231.96 |
| Basic EPS | -2.74 | -1.82 | -2.32 | -3.17 |
| Diluted EPS | -2.74 | -1.82 | -2.32 | -3.17 |
| Tax Effect Of Unusual Items | 0 | -0.28 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | -22.26 | -1.35 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | -22.26 | -1.35 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -102.25 | -70.80 | -130.87 | -231.96 |
| Reconciled Depreciation | 2.45 | 0.46 | 1.54 | 2.31 |
| Reconciled Cost Of Revenue | 7.93 | 4.63 | 3.71 | 2.07 |
| Net Interest Income | -1.06 | 5.70 | 15.07 | 11.75 |
| Net Income From Continuing And Discontinued Operation | -102.25 | -70.80 | -130.87 | -231.96 |
| Total Operating Income As Reported | -99.64 | -75.07 | -145.85 | -243.43 |
| Diluted Average Shares | 37.32 | 38.90 | 56.30 | 73.25 |
| Basic Average Shares | 37.32 | 38.90 | 56.30 | 73.25 |
| Diluted NI Availto Com Stockholders | -102.25 | -70.80 | -130.87 | -231.96 |
| Net Income Including Noncontrolling Interests | -102.25 | -70.80 | -130.87 | -231.96 |
| Net Income Continuous Operations | -102.25 | -70.80 | -130.87 | -231.96 |
| Other Income Expense | -22.26 | -1.35 | 0 | 0 |
| Special Income Charges | -22.26 | -1.35 | 0 | 0 |
| Other Special Charges | 1.56 | 1.35 | 0 | 0 |
| Impairment Of Capital Assets | 20.70 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | -1.06 | 5.70 | 15.07 | 11.75 |
| Interest Expense Non Operating | 3.19 | 1.25 | 0.01 | 0.03 |
| Interest Income Non Operating | 2.13 | 6.95 | 15.09 | 11.78 |
| Depreciation Amortization Depletion Income Statement | 2.05 | 0 | 0 | 0 |
| Depreciation And Amortization In Income Statement | 2.05 | 0 | 0 | 0 |
| Amortization | 2.05 | 0 | 0 | 0 |
| Amortization Of Intangibles Income Statement | 2.05 | 0 | 0 | 0 |
| Selling And Marketing Expense | 25.51 | 11.69 | 0.13 | 0.09 |
| General And Administrative Expense | 34.82 | 40.10 | 52.36 | 51.61 |
| Other Gand A | 34.82 | 40.10 | 52.36 | 51.61 |
| Operating Revenue | 41.40 | 46.02 | 43.27 | 31.37 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| EyePoint, Inc.this co. | EYPT | $1.1B | - | 32.47 | -75.8% | -4.95 |
| Jade Biosciences, Inc. | JBIO | $1.1B | - | 3.31 | -38.3% | -6.74 |
| InnovAge Holding Corp. | INNV | $1.1B | 161.40 | 4.27 | -11.5% | 25.32 |
| Zenas BioPharma, Inc. | ZBIO | $1.1B | - | - | -156.0% | -3.15 |
| Pacira BioSciences, Inc. | PCRX | $1.1B | 149.91 |
| 1.52 |
| 1.0% |
| 10.73 |
| CareDx, Inc. | CDNA | $1.1B | - | 3.49 | -7.0% | -124.58 |
| Teladoc Health, Inc. | TDOC | $1.1B | - | 0.77 | -14.5% | 39.94 |
| IRADIMED CORPORATION | IRMD | $1.1B | 47.83 | 11.31 | 23.8% | 37.30 |
| The Pennant Group, Inc. | PNTG | $1.1B | 36.56 | 3.22 | 7.9% | 25.85 |
| Peer Median | - | 98.87 | 3.31 | -9.3% | 18.02 | |